Abstract: Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

Abstract: Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

Abstract: Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

Abstract: A method of activating PPAR receptors in a subject, said method comprising administering to said subject an effective PPAR receptor activating amount of a pyrrolopyridine compound corresponding to formula (I): wherein R, R1, R2, R3, R4, X, Ar and n have defined meanings, or a pharmaceutically acceptable salt thereof, particularly as part of the treatment of a disorder or disease state selected from the group consisting of atherosclerosis, myocardial infarction, hypertension, and cerebral vascular disease.

Abstract: A method of activating PPAR receptors in a subject, said method comprising administering to said subject an effective PPAR receptor activating amount of a pyrrolopyridine compound corresponding to formula (I): wherein R, R1, R2, R3, R4, X, Ar and n have defined meanings, or a pharmaceutically acceptable salt thereof, particularly as part of the treatment of a disorder or disease state selected from the group consisting of atherosclerosis, myocardial infarction, hypertension, and cerebral vascular disease.

Abstract: Pyrrolopyridine compounds corresponding to formula (I): as defined in the claims, pharmaceutically acceptable salts thereof, the process for preparing such compounds, pharmaceutical compositions containing such compounds, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular diseases, inflammatory diseases and neurodegenerative diseases.

Abstract: Pyrrolopyridine compounds corresponding to formula (I): as defined in the claims, pharmaceutically acceptable salts thereof, the process for preparing such compounds, pharmaceutical compositions containing such compounds, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular diseases, inflammatory diseases and neurodegenerative diseases.

Abstract: Indole compounds corresponding to the formula (I): as defined in the claims, pharmaceutically acceptable addition salts of such compounds, pharmaceutical compositions containing such compounds, the process for their preparation, and their use as pharmacologically active substances, especially in the treatment of hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, diabetes, endothelial dysfunction, cardiovascular disease, inflammatory disease and neurodegeneration.

Abstract: The invention concerns (i) [4-(4-cyanobenzyl)phenyl]&agr;-D-glycopyranosides of formula (I) wherein: the group &agr;-D-glycopyranosyl R represents a &agr;-D-glycopyranosyl, &agr;-D-galactopyranosyl. &agr;-D-mannopyranosyl, &agr;-D-arabinopyranosyl, &agr;-D-lyxopyranosyl, or &agr;-D-ribopyranosyl group: (ii) their esters resulting from the esterification of at least a OH function of each pyranosyl group with a C2-C4 alkanoic or a cycloalkanoic acid, as novel industrial products. Said novel [4-(4-cyanobenzyl)phenyl]&agr;-D-glycopyranosides are useful in therapy for fighting against atheromatous plaque.

Abstract: The invention concerns: (i) [4-(4-cyanobenzyl)phenyl]glycopyranosides of formula (I) wherein; the glycopyranosyl group R represents a &bgr;-D arabinopyranosyl, &bgr;-D-lyxopyranosyl, &bgr;-D-ribopyranosyl, &bgr;-D-mannopyranosyl, &bgr;-L-arabinopyranosyl, &bgr;-L-xylopyranosyl, &agr;-L-arabinopyranosyl, &agr;-L-xylopyranosyl or &bgr;-L-rhamnopyranosyl group; and (ii) their esters resulting from esterification of at least a OH function of each glycopyranosyl group with a C2-C4 alkanoic or cycloalkanoic acid, as novel industrial products. Said novel [4-(4-cyanobenzyl)phenyl]glycopyranosides are useful in therapy for fighting against athermatous plaque.

Abstract: The present invention concerns, as new industrial products, the &agr;-D-xylose compounds of formula I: wherein X and Y represent, independently of one another, an oxygen atom or a sulphur atom, R1 represents a CN, CF3 or SO2CH3 group, and R represents a hydrogen atom or an aliphatic acyl group containing 2 to 5 carbon atoms. It also concerns a method for the preparation and the use in therapeutics of said compounds of the formula I.